INTRODUCTION
============

IP~3~Rs \[IP~3~ (inositol 1,4,5-trisphosphate) receptors\] and RyRs (ryanodine receptors) are related families of intracellular Ca^2+^ channels (see Supplementary Figure S1 at <http://www.biochemj.org/bj/451/bj4510177add.htm>). IP~3~Rs are expressed in most animal cells \[[@B1]\] and RyRs are expressed in many cells, but most abundantly in excitable tissues \[[@B2]\]. Most IP~3~Rs and RyRs are expressed within the membranes of the endoplasmic or sarcoplasmic reticulum, where they mediate the release of Ca^2+^ stored within them. Vertebrate genomes have three genes for IP~3~R subunits and most have three genes for RyR. Functional intracellular Ca^2+^ channels are tetrameric assemblies of these very large subunits, probably only homotetramers for RyR \[[@B2]\] (but see \[[@B3]\]), whereas IP~3~R form both homo- and hetero-tetrameric channels \[[@B1]\]. Activation of IP~3~R is initiated by binding of IP~3~ to the IBC (IP~3~-binding core; residues 224--604) of each IP~3~R subunit \[[@B4]\] and then proceeds via re-arrangement of an interface between the IBC and SD (suppressor domain; residues 1--223) \[[@B5],[@B6]\] (see Supplementary Figure S1). The links between these conformational changes within the NT (N-terminal residues 1--604) domains of the IP~3~R and gating of the channel formed by transmembrane helices close to the C-terminal are poorly understood, but they are known to require the SD \[[@B7]\].

The two families of intracellular Ca^2+^ channels, IP~3~Rs and RyRs, share many characteristics including related structures \[[@B6]\], similar pores \[[@B8]\] and many aspects of their regulation. The latter includes regulation by cytosolic Ca^2+^ \[[@B9],[@B10]\] and modulation by thiol-reactive reagents \[[@B11],[@B12]\]. Indeed, modification of cysteinyl residues within ion channels is widespread \[[@B13]--[@B17]\], and contributes both to pathological responses to oxidative stress \[[@B18]\] and to physiological signals, including nitric oxide \[[@B19]\], hydrogen peroxide \[[@B20]\] and oxygen \[[@B21]\], which generate reactive oxygen or nitrogen species (see references in \[[@B22]\]).

Thimerosal (also known as thiomersal) was once widely used as an antiseptic and as a preservative, particularly in childhood vaccines, but after considerable controversy it is now rarely used \[[@B23]\]. However, as a membrane-permeable thiol-oxidizing agent, thimerosal remains a useful experimental tool that interacts with free thiol groups to form a thiomercuryethyl complex. Many studies have reported thimerosal-evoked increases in cytosolic Ca^2+^ concentration and suggested that they, at least partly, result from its effects, whether direct or via oxidation of GSH, on IP~3~Rs or RyRs (reviewed in \[[@B24]\]).

Many thiol reagents, including thimerosal \[[@B25]\], biphasically regulate RyR activity: low concentrations stimulate activity, whereas higher concentrations are inhibitory \[[@B12],[@B22]\]. This pattern is reminiscent of the biphasic regulation of RyR by cytosolic Ca^2+^ \[[@B10]\], and consistent with evidence that oxidation of critical cysteine residues increases the sensitivity of RyRs to endogenous regulators \[[@B26]\] (reviewed in \[[@B12]\]). There are approximately 100 cysteine residues in each RyR subunit and within the reducing environment of the cytosol approximately half of these are in the reduced state \[[@B22]\]. A few of these residues are particularly susceptible to oxidation, and their susceptibility depends on whether the RyR is open or closed. But there is not yet any clearly defined relationship between oxidation of specific cysteine residues and channel activity (reviewed in \[[@B12]\]).

An abundant amount of evidence demonstrates that IP~3~R activity is also modulated by thiol-oxidizing agents \[[@B27]\] (reviewed in \[[@B11]\]). In many cells, for example, the effects of thimerosal on IP~3~-evoked Ca^2+^ release are rather similar to its biphasic effects on RyRs: potentiation of responses at low concentrations and inhibition of Ca^2+^ release at higher concentrations of thimerosal \[[@B11]\]. Although the responses to thimerosal in intact cells are undoubtedly made more complicated by its effects on additional Ca^2+^-handing proteins and perturbation of GSH/GSSG \[[@B28]\], there are clearly direct biphasic effects on IP~3~R behaviour \[[@B29]\] (see references in \[[@B11]\]). There are 60 cysteine residues in each IP~3~R1 subunit and most are likely to be in the reduced form in their native setting \[[@B11]\]. None of the 12 cysteine residues within the S1 splice variant of the IP~3~R1 NT are required for effective gating of IP~3~Rs by IP~3~ \[[@B6]\], but two conserved cysteine residues within the C-terminal tail (Cys^2610^ and Cys^2613^) are essential \[[@B7]\], and three reduced cysteine residues within the third luminal loop of IP~3~R1 (Cys^2496^, Cys^2504^ and Cys^2527^) are essential for its redox-sensitive interaction with a luminal thioredoxin-related protein, ERp44 \[[@B30]\]. The mechanisms whereby thimerosal or other thiol reagents modulate IP~3~R behaviour have not been resolved, but they are relevant to understanding redox regulation of IP~3~Rs under physiological and pathological conditions, and to defining further the mechanisms of IP~3~R activation. The mechanism by which thimerosal regulates the three subtypes of IP~3~Rs is addressed in the present study.

MATERIALS AND METHODS
=====================

Materials
---------

Thimerosal and heparin (sodium salt from bovine intestinal mucosa) were from Sigma--Aldrich. IP~3~ was from Enzo Life Sciences (Exeter). \[^3^H\]IP~3~ (18 Ci/mmol) was from PerkinElmer Life and Analytical Sciences. Dimeric IP~3~ (structure shown in [Figure 3](#F3){ref-type="fig"}A) was synthesized and characterized as reported previously \[[@B5]\]. Sources of other materials are specified in previous publications \[[@B31],[@B32]\] or within the relevant methods sections.

Expression of NT fragments of IP~3~ receptors
---------------------------------------------

NT fragments of rat IP~3~R1 (NT1 and IBC) (Supplementary Table S1 at <http://www.biochemj.org/bj/451/bj4510177add.htm>) were amplified by PCR from the full-length coding sequence of IP~3~R1 lacking the S1 splice site (GenBank accession number: GQ233032.1) and ligated into pGEX-6P-2 vectors (GE Healthcare). The open reading frame encoding NT2 (residues 1--604 from mouse IP~3~R2) (GenBank: GU980658.1) and NT3 (residues 1--604 from rat IP~3~R3) (GenBank: GQ233031.1) were amplified by PCR using the primers listed in Supplementary Table S2 (at <http://www.biochemj.org/bj/451/bj4510177add.htm>). PCR products were digested with SmaI and XhoI and ligated into pGEX-6P-2 vectors for expression in *Escherichia coli.* The methods used to express an NT1^CL^ (cysteine-less NT1) in which all endogenous cysteine residues of the NT of IP~3~R1 were replaced by alanine, and a chimaeric NT (RyR2A-IBC) in which the A domain of the type 2 RyR (RyR2; residues 1--210) (GenBank: GI164831) \[[@B33]\] was fused to the IBC of rat IP~3~R1 were described recently \[[@B6]\]. The plasmid encoding NT1^CL−IBC^ (NT1 where cysteine residues within the IBC were replaced by alanine) (Supplementary Table S1) was generated from the NT1 construct using QuikChange multi-site-directed mutagenesis (Agilent). The NT1^CL^ construct was used as the template to prepare a plasmid encoding NT1^CL−SD^ (NT1 where all endogenous cysteine residues within the SD were replaced by alanine) (Supplementary Table S1). The sequence encoding the cysteine-less SD was PCR-amplified from the NT1^CL^ template using the primers listed in Supplementary Table S2. PCR products were then ligated into the pET41a(+) vector containing the open reading frame of the IBC of IP~3~R1 as SpeI/EcoRV fragments for expression in *E. coli*. The coding sequences of all expression constructs were confirmed. Supplementary Table S1 lists the proteins used and their abbreviations.

All N-terminal fragments of IP~3~R were expressed as fusion proteins linked to N-terminal GST (glutathione transferase) via a PreScission cleavage site in *E. coli* BL21 (DE3) exactly as described previously \[[@B32]\]. Bacteria were harvested (6000 ***g*** for 15 min at 4°C), washed twice with phosphate-buffered saline and stored at −80°C before purification of the fragments. Bacterial pellets were suspended (1 g/10 ml) in Tris-buffered medium \[50 mM Tris and 1 mM EDTA (pH 8.3)\] and lysed by incubation with 100 μg/ml lysozyme (Sigma--Aldrich), 5 units/ml DNase (Sigma--Aldrich) and 10 μg/ml RNase (Sigma--Aldrich) for 1 h on ice, followed by sonication (30 s). After centrifugation (30000 ***g*** for 60 min at 4°C), the supernatant was mixed with glutathione--Sepharose 4B beads \[GE Healthcare; lysate/beads (v/v) 50:1) and incubated with gentle rotation for 1 h at 20°C. The beads were then washed with Tris-buffered medium supplemented with 1 mM dithiothreitol, centrifuged (500 ***g*** for 5 min at 4°C) and incubated in the same medium (1 ml) supplemented with 160 units/ml GST-tagged PreScission protease (GE Healthcare) for 16 h at 4°C with gentle rotation. After centrifugation (500 ***g*** for 5 min at 4°C), the NT fragments, cleaved from their GST tags, were recovered in the supernatant and rapidly frozen in liquid nitrogen before storage at −80°C. Immunoblots of the proteins used are shown in Supplementary Figure S3 (at <http://www.biochemj.org/bj/451/bj4510177add.htm>).

\[^3^H\]IP~3~ binding
---------------------

Equilibrium competition binding assays were performed in Tris-buffered medium (500 μl) containing purified protein (1--5 μg), \[^3^H\]IP~3~ (0.25--0.75 nM) and appropriate concentrations of competing ligand. Where indicated, thimerosal was added 10 min before the addition of \[^3^H\]IP~3~. Reactions were terminated after 5 min by addition of poly(ethylene glycol)-8000 \[Sigma--Aldrich; 30% (w/v) 500 μl\] and γ-globulin (Sigma--Aldrich; 750 μg in 30 μl of Tris-buffered medium). Bound and free \[^3^H\]IP~3~ were then separated by centrifugation (20000 ***g*** for 5 min). Results were fitted to Hill equations using GraphPad Prism (version 5.0, GraphPad) from which IC~50~, and thereby *K*~d~ (equilibrium dissociation constant) and p*K*~d~, values were calculated.

Ca^2+^ release from the intracellular stores of DT40 cells expressing IP~3~R subtypes
-------------------------------------------------------------------------------------

DT40 cells, in which the genes for all three endogenous IP~3~R subtypes had been disrupted \[DT40-KO (knockout) cells\], were used to generate stable cell lines expressing rat IP~3~R1, mouse IP~3~R2 or rat IP~3~R3 (DT40-IP~3~R1--3 cells) or a chimaeric IP~3~R (RyR1A-IP~3~R1) in which the SD of IP~3~R1 was replaced by the equivalent A domain of rabbit type 1 RyR (RyR1; residues 1---210; GenBank accession number: X15209) (DT40-RyR1A-IP~3~R1 cells) (Supplementary Table S1). The methods used to establish these stable cell lines have been described previously \[[@B6],[@B34]\]. All DT40 cells were grown in suspension at 37°C in an atmosphere of 95% air and 5% CO~2~ in RPMI 1640 medium supplemented with 2 mM [l]{.smallcaps}-glutamine, 10% fetal bovine serum, 1% heat-inactivated chicken serum and 50 μM 2-mercaptoethanol. Cells were used or passaged when they reached a density of \~2×10^6^ cells/ml. Expression levels of IP~3~Rs in the cell lines were compared by immunoblotting using antisera selective for each IP~3~R subtype or an anti-peptide serum (AbC) that interacts equally with all three IP~3~R subtypes. The immunoblotting methods were reported previously \[[@B34]\].

A low-affinity Ca^2+^ indicator, Mag-fluo-4, trapped within the endoplasmic reticulum, was used to measure luminal free Ca^2+^ concentration \[[@B31]\]. The endoplasmic reticulum of DT40 cells (\~4×10^6^ cells/ml) was loaded with indicator by incubating cells in the dark (for 1 h at 20°C) with 20 μM Mag-fluo-4/AM (acetoxymethyl ester) in Hepes-buffered saline \[135 mM NaCl, 5.9 mM KCl, 11.6 mM Hepes, 1.5 mM CaCl~2~, 11.5 mM glucose and 1.2 mM MgCl~2~ (pH 7.3)\], supplemented with Pluronic F127 (1 mg/ml) and BSA (0.4 mg/ml). After centrifugation (650 ***g*** for 2 min), cells (\~4×10^6^ cells/ml) were suspended in Ca^2+^-free CLM \[cytosol-like medium; 140 mM KCl, 20 mM NaCl, 2 mM MgCl~2~, 1 mM EGTA and 20 mM Pipes (pH 7.0)\], supplemented with saponin (final concentration 20 μg/ml) to allow for selective permeabilization of the plasma membrane. After \~4 min at 37°C, when all cells had become permeable to 0.1% Trypan Blue, the cells (5×10^5^ cells/ml) were recovered (650 ***g*** for 2 min) and suspended at 20°C in Mg^2+^-free CLM, supplemented with CaCl~2~ (375 μM, to provide a final free Ca^2+^ concentration of 220 nM after addition of 1.5 mM MgATP) and 10 μM FCCP (carbonyl cyanide *p*-trifluoromethoxyphenylhydrazone). The cells were then distributed into poly-[l]{.smallcaps}-lysine-coated 96-well plates (50 μl/well), centrifuged (300 ***g*** for 2 min) and used for fluorescence measurements. Fluorescence (excitation 485 nm, emission 520 nm, measured at 1.5 s intervals) was recorded at 20°C using a FlexStation III plate-reader (Molecular Devices) \[[@B31]\]. MgATP (1.5 mM) was added to allow intracellular stores to sequester Ca^2+^. After the stores had loaded to steady state (\~150 s), IP~3~ was added with thapsigargin (1 μM to inhibit Ca^2+^ re-uptake). Ca^2+^ release was measured after a further 60 s. The Ca^2+^ release evoked by IP~3~ is expressed as a fraction of the ATP-dependent Ca^2+^ uptake \[[@B31]\]. Concentration--effect relationships were fitted to Hill equations using non-linear curve fitting (version 5.0, GraphPad Prism).

Statistical analyses of IP~3~R sensitivity to IP~3~ used pEC~50~ and p*K*~d~ values (negative logarithm of the EC~50~ and *K*~d~ respectively). Results are presented as means±S.E.M. For clarity, mean EC~50~ and *K*~d~ values (derived from pEC~50~ or p*K*~d~) are shown alongside. In paired comparisons of the effects of thimerosal, ΔpEC~50~ (or Δp*K*~d~) values are shown, where ΔpEC~50~=EC~50~^thimerosal^−pEC~50~^control^. Statistical analyses used ANOVA followed by paired Student\'s *t* test. *P*\<0.05 was considered significant.

RESULTS AND DISCUSSION
======================

Thimerosal potentiates IP~3~-evoked Ca^2+^ release via IP~3~R1 and IP~3~R2
--------------------------------------------------------------------------

In DT40 cells stably expressing only IP~3~R1 (DT40-IP~3~R1 cells) ([Figure 1](#F1){ref-type="fig"}A), IP~3~ caused a concentration-dependent release of Ca^2+^ from intracellular stores (pEC~50~=7.95±0.04) ([Figure 1](#F1){ref-type="fig"}B). Pre-incubation with thimerosal (10 μM for 120 s) increased the sensitivity to IP~3~ (pEC~50~=8.95±0.31, ΔpEC~50~=1.00±0.32) without affecting loading of the Ca^2+^ stores or the maximal response to IP~3~ ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}B). Similar results were obtained with DT40 cells expressing only IP~3~R2 (DT40-IP~3~R2 cells) ([Figure 1](#F1){ref-type="fig"}A), where 10 μM thimerosal also increased the sensitivity to IP~3~ (ΔpEC~50~=0.60±0.20) ([Figure 1](#F1){ref-type="fig"}C). For both IP~3~R1 and IP~3~R2, higher concentrations of thimerosal inhibited responses to IP~3~ ([Table 1](#T1){ref-type="table"}). However, in DT40 cells expressing IP~3~R3 (DT40-IP~3~R3 cells) ([Figure 1](#F1){ref-type="fig"}A), 10 μM thimerosal inhibited IP~3~-evoked Ca^2+^ release (ΔpEC~50~=−0.17±0.01) ([Figure 1](#F1){ref-type="fig"}D), without significantly affecting loading of the intracellular Ca^2+^ stores ([Table 1](#T1){ref-type="table"}). The latter demonstrates that the diminished responses to IP~3~ were not due to thimerosal activating IP~3~R3 and thereby draining the Ca^2+^ stores before addition of IP~3~. Functional effects of thimerosal were reported previously for DT40 cells expressing IP~3~R1 or IP~3~R3 \[[@B29]\], but use of the same single sub-threshold concentration of IP~3~ for both IP~3~R subtypes when IP~3~R3 is much less sensitive to IP~3~ ([Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) \[[@B35]\] compromised the conclusion that thimerosal sensitizes only IP~3~R1. Our results, demonstrating that low concentrations of thimerosal sensitize IP~3~R1 and IP~3~R2 to IP~3~ while inhibiting IP~3~R3, are consistent with previous studies in which thimerosal \[[@B29],[@B36]--[@B42]\] or other thiol reagents \[[@B40],[@B43],[@B44]\] potentiated IP~3~-evoked Ca^2+^ signals in cells expressing predominantly IP~3~R1 \[[@B29],[@B37],[@B42]\] or IP~3~R2 \[[@B38],[@B40],[@B43],[@B44]\], but not in cells where IP~3~R3 predominates \[[@B29],[@B39],[@B41]\]. We conclude that within homotetrameric populations of IP~3~R, thimerosal potentiates responses from IP~3~R1 and IP~3~R2, but inhibits IP~3~R3.

![IP~3~-evoked Ca^2+^ release via IP~3~R1 and IP~3~R2 is sensitized by thimerosal\
(**A**) Immunoblot (4×10^4^ cells/lane) using an antiserum (AbC) that recognizes a conserved NT sequence in all IP~3~R subtypes demonstrates that expression levels of the three IP~3~R subtypes and chimaeric IP~3~R are broadly similar in each of the four cell lines. There are no detectable IP~3~Rs in the DT40-KO cells. (**B**--**D**) Concentration-dependent effects of IP~3~ on Ca^2+^ release are shown for control cells and after treatment with thimerosal (10 μM, 2 min) for DT40 cells expressing each of the three IP~3~R subtypes. Results are means±S.E.M. for at least three independent experiments. The structure of thimerosal is shown within (**B**). ○, control; ●, thimerosal.](bj2012-1600i001){#F1}

###### Effects of thimerosal on IP~3~-evoked Ca^2+^ release by different IP~3~Rs

DT40 cells expressing each of the IP~3~R subtypes were incubated with the indicated concentrations of thimerosal during loading of the intracellular stores with Ca^2+^ (2 min) before addition of IP~3~. Results show Ca^2+^ uptake (as a percentage of its value in the absence of thimerosal), maximal IP~3~-evoked Ca^2+^ release (as a percentage of the Ca^2+^ content of the stores before addition of IP~3~) and the Hill coefficient (*h*), pEC~50~ and EC~50~ values for the IP~3~-evoked Ca^2+^ release. All results (except EC~50~, which shows only the mean, see the Materials and methods section) are shown as means±S.E.M. for three to four independent experiments. ND, not determined.

  IP~3~R subtypes   Thimerosal (μM)   Ca^2+^ uptake (%)                        EC~50~ (nM)   pEC~50~                                       *h*       Maximal Ca^2+^ release (%)
  ----------------- ----------------- ---------------------------------------- ------------- --------------------------------------------- --------- -----------------------------------------
  IP~3~R1           0                 100                                      11            7.95±0.04                                     2.0±0.1   84±2
                    1                 98±5                                     7             8.16±0.13                                     1.2±0.2   89±1[\*](#T1TFN1){ref-type="table-fn"}
                    10                97±7                                     1             8.95±0.31[\*](#T1TFN1){ref-type="table-fn"}   2.7±0.8   85±2
                    100               93±6                                     77            7.11±0.18[\*](#T1TFN1){ref-type="table-fn"}   1.0±0.4   42±11[\*](#T1TFN1){ref-type="table-fn"}
                                                                                                                                                     
  IP~3~R2           0                 100                                      23            7.64±0.01                                     1.6±0.1   74±2
                    1                 99±2                                     14            7.87±0.22                                     1.3±0.2   78±3
                    10                96±7                                     6             8.24±0.26[\*](#T1TFN1){ref-type="table-fn"}   2.2±0.3   77±4
                    100               93±3                                     35            7.46±0.28                                     0.9±0.2   67±2[\*](#T1TFN1){ref-type="table-fn"}
                                                                                                                                                     
  IP~3~R3           0                 100                                      576           6.24±0.04                                     1.2±0.1   88±2
                    1                 99±3                                     687           6.16±0.08                                     1.0±0.1   90±5
                    10                97±8                                     860           6.07±0.06[\*](#T1TFN1){ref-type="table-fn"}   1.3±0.1   78±8
                    100               86±6                                     2185          5.66±0.02[\*](#T1TFN1){ref-type="table-fn"}   3.0±0.5   54±2[\*](#T1TFN1){ref-type="table-fn"}
                                                                                                                                                     
  RyR1A-IP~3~R1     0                 100                                      65            7.19±0.01                                     2.4±0.1   81±4
                    1                 97±4                                     78            7.11±0.04                                     2.0±0.2   76±3
                    10                89±4                                     238           6.62±0.18[\*](#T1TFN1){ref-type="table-fn"}   1.6±0.2   80±6
                    100               66±8[\*](#T1TFN1){ref-type="table-fn"}   ND            ND                                            ND        12±1^≠^

\**P*\<0.05 relative to its control. ^≠^Response to 1 μM IP~3~.

Thimerosal stimulates IP~3~ binding to the NTs of IP~3~R1 and IP~3~R2
---------------------------------------------------------------------

Thimerosal stimulates IP~3~-evoked Ca^2+^ release via purified IP~3~R1 \[[@B37]\] and it stimulates \[^3^H\]IP~3~ binding to purified IP~3~R1 \[[@B37]\] and its isolated NT \[[@B29]\]. This confirms that thimerosal directly affects IP~3~R1. Activation of IP~3~R is initiated by IP~3~ binding to the IBC and proceeds via re-arrangement of interactions between the IBC and SD \[[@B6]\]. We therefore examined \[^3^H\]IP~3~ binding to the NTs of IP~3~R1--IP~3~R3, a region that comprises the critical SD and IBC (Supplementary Figure S1A).

Incubation (10 min) of purified NT from IP~3~R1 (NT1) with thimerosal caused a concentration-dependent stimulation of \[^3^H\]IP~3~ binding that was maximal with 100 μM thimerosal and then reversed at higher concentrations ([Figure 2](#F2){ref-type="fig"}A). A biphasic effect of thimerosal on \[^3^H\]IP~3~ binding to full-length IP~3~R1 \[[@B45]\] and an NT region of IP~3~R1 (residues 1--581) was reported previously \[[@B46]\]. The maximally effective concentration of thimerosal (100 μM) caused a 12-fold increase in the affinity of NT1 for IP~3~ (Δp*K*~d~=1.07±0.28) ([Figure 2](#F2){ref-type="fig"}B and [Table 2](#T2){ref-type="table"}). The effect of maximally effective concentrations of thimerosal (10--100 μM) on the sensitivities of functional responses of IP~3~R1 to IP~3~ (ΔpEC~50~=1.00±0.32) and IP~3~ binding to NT1 (Δp*K*~d~=1.07±0.28) are similar: both are increased \~10-fold. The results were similar with IP~3~R2: 100 μM thimerosal caused a \~10-fold increase in the affinity of NT2 for IP~3~ (Δp*K*~d~=1.05±0.19) ([Figure 2](#F2){ref-type="fig"}C and [Table 2](#T2){ref-type="table"}). There was no significant effect of thimerosal on IP~3~ binding to the NT of IP~3~R3 ([Figure 2](#F2){ref-type="fig"}D and [Table 2](#T2){ref-type="table"}).

![Thimerosal stimulates \[^3^H\]IP~3~ binding to the NT of IP~3~R1 and IP~3~R2\
(**A**) Specific binding of \[^3^H\]IP~3~ (0.5 nM) to the NT of IP~3~R1 is shown after pre-incubation (10 min) with the indicated concentrations of thimerosal. Results are shown as the percentage of specific \[^3^H\]IP~3~ binding measured in the absence of thimerosal. (**B**--**D**) Concentration-dependent effects of IP~3~ on specific \[^3^H\]IP~3~ binding (0.5 nM) to the NT from each of the three IP~3~R subtypes alone or after incubation with thimerosal (100 μM, 10 min). (**A**--**D**) Results are means±S.E.M. for four independent experiments. ○, control; ●, thimerosal.](bj2012-1600i002){#F2}

###### Effects of thimerosal on \[^3^H\]IP~3~ binding to the NT of each IP~3~R subtype

Equilibrium-competition binding experiments using \[^3^H\]IP~3~ (0.5 nM) and NT1--NT3 show the effects of thimerosal (100 μM, 10 min) on the *K*~d~ (mean), p*K*~d~ (mean±S.E.M.) and Hill coefficient (*h*, mean±S.E.M.) for IP~3~. Δp*K*~d~=p*K*~d~^thimerosal^−p*K*~d~^control^. Results are from at least four independent experiments.

        p*K*~d~ (*K*~d~; nM) *h*                                                  
  ----- -------------------------- ---------------------------------------------- -----------
  NT1   8.62±0.10                  9.69±0.26[\*](#T2TFN1){ref-type="table-fn"}    1.07±0.28
        (2.39)                     (0.20)                                         
        1.2±0.2                    1.2±0.3                                        
  NT2   9.12±0.07                  10.17±0.15[\*](#T2TFN1){ref-type="table-fn"}   1.05±0.19
        (0.76)                     (0.07)                                         
        0.6±0.04                   0.6±0.02                                       
  NT3   8.06±0.06                  7.91±0.17                                      0.15±0.22
        (8.72)                     (12.4)                                         
        0.7±0.06                   1.0±0.05                                       

\**P*\<0.05 relative to its control.

Previous work suggested that thimerosal stimulates \[^3^H\]IP~3~ binding to full-length IP~3~R1, but not to IP~3~R3, whereas it stimulated binding to the NT region (residues 1--581) of IP~3~R1 and IP~3~R3, but not to that of IP~3~R2 \[[@B29],[@B46]\]. The previous conclusions are neither internally consistent nor consistent with our observations using NT1--NT3 (residues 1--604) ([Figure 2](#F2){ref-type="fig"}). The residues missing in the shorter NT fragments are reasonably conserved between IP~3~R subtypes and they lack cysteine residues (Supplementary Figure S1B). However, from the high-resolution structure of the IBC \[[@B4]\], an NT region truncated at residue 581 is likely to disrupt an α-helix (α9 in \[[@B4]\]), the NT of which forms essential interactions with IP~3~. Furthermore, the published affinities for IP~3~ of these shorter fragments from IP~3~R1 and IP~3~R3 are indistinguishable, which is inconsistent with evidence that in both NT and full-length proteins, IP~3~R3 has lower affinity than IP~3~R1 \[[@B35]\] ([Table 2](#T2){ref-type="table"}). It seems likely that the shorter fragments used in the previous studies \[[@B29],[@B46]\] may not retain the native structure of the IBC.

Our results with \[^3^H\]IP~3~ binding to the NT from all three IP~3~R subtypes ([Figure 2](#F2){ref-type="fig"}), evidence from \[^3^H\]IP~3~ binding to full-length IP~3~R1 and IP~3~R3 expressed in Sf9 insect cells \[[@B29]\], our functional analyses of DT40 cells expressing homogenous populations of IP~3~R subtypes ([Figure 1](#F1){ref-type="fig"}) and substantial evidence from native cells expressing different IP~3~R subtypes (discussed above) are consistent with the conclusion that low concentrations of thimerosal stimulate IP~3~ binding and IP~3~-evoked Ca^2+^ release via IP~3~R1 and IP~3~R2, but not via IP~3~R3. These observations support the hypothesis that cysteine residues within the NT of IP~3~R1 and IP~3~R2 mediate the sensitizing effects of thimerosal on IP~3~-evoked Ca^2+^ release. Subsequent experiments address this hypothesis.

Thimerosal stimulates agonist, but not antagonist, binding to the NT of IP~3~R1
-------------------------------------------------------------------------------

Heparin is a competitive antagonist of IP~3~R \[[@B47]\], and dimeric IP~3~ (see [Figure 3](#F3){ref-type="fig"}A for structure) is a high-affinity partial agonist: the IP~3~ dimer binds to the IP~3~R, but causes lesser activation than IP~3~ such that the channel opens less frequently \[[@B5]\]. Both heparin and IP~3~ dimer completely displaced specifically bound \[^3^H\]IP~3~ from NT1, but thimerosal (100 μM, 10 min) affected the affinity of neither: Δp*K*~d~ was 0.11±0.09 and −0.06±0.19 for heparin and IP~3~ dimer respectively ([Figure 3](#F3){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). These results are important because they demonstrate that thimerosal selectively affects the binding of ligands that activate IP~3~R. It is, however, noteworthy that thimerosal alone does not activate IP~3~R. Concentrations of thimerosal (≤10 μM) that cause substantial sensitization of IP~3~R1 and IP~3~R2 do not affect the Ca^2+^ content of the stores in the absence of IP~3~ ([Table 1](#T1){ref-type="table"}). These results suggest that thimerosal might selectively stabilize an agonist-bound active conformation of IP~3~R1.

![Thimerosal does not affect binding of an antagonist or partial agonist\
(**A** and **B**) Concentration-dependent effects of the IP~3~ dimer (**A**) or heparin (**B**) on specific \[^3^H\]IP~3~ binding (0.25 nM) to the NT from IP~3~R1 alone or after incubation with thimerosal (100 μM, 10 min). Results are means±S.E.M. for four independent experiments. The structure of the IP~3~ dimer is shown within (**A**). ○, control; ●, thimerosal.](bj2012-1600i003){#F3}

###### Effects of thimerosal on binding of heparin and IP~3~ dimer to the NT from IP~3~R1

Equilibrium-competition binding experiments using \[^3^H\]IP~3~ (0.25 nM) and NT1 show the effects of thimerosal (100 μM, 10 min) on the *K*~d~ (mean), p*K*~d~ (mean±S.E.M.) and Hill coefficient (*h*, mean±S.E.M.) for IP~3~ dimer and heparin. Δp*K*~d=~ p*K*~d~^thimerosal^−p*K*~d~^control^. Results are from ≥four independent experiments.

                p*K*~d~ (*K*~d~) *h*                
  ------------- ---------------------- ------------ ------------
  IP~3~ dimer   9.81±0.07              9.75±0.14    −0.06±0.19
                (0.15 nM)              (0.18 nM)    
                1.2±0.1                1.7±0.4      
  Heparin       7.06±0.09              7.17±0.03    0.11±0.09
                (87 ng/ml)             (68 ng/ml)   
                0.82±0.17              0.73±0.09    

Cysteine residues within both the SD and IBC are required for thimerosal to stimulate IP~3~ binding
---------------------------------------------------------------------------------------------------

Previous work demonstrated that thimerosal stimulates \[^3^H\]IP~3~ binding to NT1, but not to the IBC \[[@B29]\]. Results shown in [Figure 4](#F4){ref-type="fig"} confirm that conclusion. We have shown that NT1^CL^ is structurally and functionally indistinguishable from native NT1 \[[@B6]\]. The lack of effect of thimerosal on \[^3^H\]IP~3~ binding to NT1^CL^ ([Figure 4](#F4){ref-type="fig"}A) confirms that cysteine residues mediate its effects. We had anticipated, in keeping with earlier evidence \[[@B29]\], that cysteine residues within the SD were likely to mediate the effects of thimerosal. However, thimerosal had no effect on \[^3^H\]IP~3~ binding to NT lacking cysteine in either the SD (NT1^CL−SD^) or the IBC (NT1^CL−IBC^) ([Figures 4](#F4){ref-type="fig"}B and [4](#F4){ref-type="fig"}C). These results demonstrate that stimulation of IP~3~ binding by thimerosal requires cysteine residues within both the SD and IBC.

![Stimulation of IP~3~ binding by thimerosal requires cysteine residues within the SD and IBC\
(**A**) Effects of thimerosal (100 μM, 10 min) on specific binding of \[^3^H\]IP~3~ (0.5 nM) to each of the indicated proteins. Results are expressed as a percentage of the binding measured in the absence of thimerosal. (**B** and **C**) Concentration-dependent effects of thimerosal on specific \[^3^H\]IP~3~ binding to NT1^CL−SD^ (**B**) and NT1^CL−IBC^ (**C**). All results are means±S.E.M. for four independent experiments.](bj2012-1600i004){#F4}

Residues within the NT are required for thimerosal to potentiate IP~3~-evoked Ca^2+^ release
--------------------------------------------------------------------------------------------

It would be instructive to examine the functional effects of thimerosal on full-length IP~3~R1 in which cysteine residues within the NT are replaced by alanine and so verify whether the NT mediates the effects of thimerosal on IP~3~-evoked Ca^2+^ release. We have demonstrated that IP~3~R1 with a cysteine-less NT is functional, but only in transiently transfected DT40-KO cells \[[@B6]\], in which it is impracticable to complete the concentration--effect relationships needed to define the effects of thimerosal. We have not yet succeeded in establishing stable DT40 cell lines expressing IP~3~R1 with a cysteine-less NT. We therefore adopted another approach and used a stable DT40 cell line expressing a chimaeric IP~3~R1 in which the native SD is replaced by the equivalent region (the A domain) from a RyR (RyR1A-IP~3~R1) \[[@B6]\] ([Figure 5](#F5){ref-type="fig"}A, and Supplementary Table S1).

![A chimaeric IP~3~R1 is not stimulated by thimerosal\
(**A**) The proteins used. (**B**) Concentration-dependent effects of thimerosal on specific \[^3^H\]IP~3~ (0.5 nM) binding to RyR2A-IBC. Results are expressed as percentages of the binding measured in the absence of thimerosal. (**C**) Concentration-dependent effects of IP~3~ on Ca^2+^ release from DT40-RyR1A-IP~3~R1 cells are shown for control cells and after treatment with thimerosal (10 μM, 2 min). Results in (**B** and **C**) are means±S.E.M. from four independent experiments.](bj2012-1600i005){#F5}

The A domain of RyR, which is structurally similar to the SD of IP~3~R \[[@B6],[@B48]--[@B50]\] (Supplementary Figure S1C and S1D), can functionally replace the SD of IP~3~R1 to allow both IP~3~-evoked Ca^2+^ release from a chimaeric IP~3~R and appropriate regulation of IP~3~ binding to a chimaeric NT \[[@B6]\]. All effective concentrations of thimerosal (1 μM--1 mM) inhibited \[^3^H\]IP~3~ binding to the chimaeric NT (RyR2A-IBC) ([Figures 5](#F5){ref-type="fig"}A and [5](#F5){ref-type="fig"}B), although the effect appeared biphasic. Thimerosal (10 μM, 2 min) also inhibited IP~3~-evoked Ca^2+^ release from the chimaeric IP~3~R (RyR1A-IP~3~R1) ([Figure 5](#F5){ref-type="fig"}C and [Table 1](#T1){ref-type="table"}). These results suggest that these cysteine residues present within the SD of IP~3~R1, but absent from the A domain of RyR, are required for thimerosal to potentiate IP~3~-evoked Ca^2+^ release.

Conclusions
-----------

Thimerosal potentiates IP~3~-evoked Ca^2+^ release via IP~3~R1 and IP~3~R2, but not via IP~3~R3 ([Figure 1](#F1){ref-type="fig"}). The parallel behaviour of NTs from each of the three IP~3~R subtypes ([Figure 2](#F2){ref-type="fig"}), our demonstration that cysteine residues are required within both the IBC and SD for thimerosal to stimulate IP~3~ binding ([Figure 4](#F4){ref-type="fig"}) and evidence that thimerosal does not potentiate responses from a chimaeric IP~3~R1 in which the SD is replaced by the equivalent domain of a RyR ([Figure 5](#F5){ref-type="fig"}) provide persuasive evidence that cysteine residues within the SD and IBC mediate functional responses to thimerosal. Furthermore, thimerosal selectively stimulates agonist, but not antagonist, binding to NT1 ([Figure 3](#F3){ref-type="fig"}), suggesting that its interactions with critical cysteine residues selectively stabilize an active conformation of the NT. Because IP~3~ binding re-arranges interactions between the SD and IBC \[[@B6]\], this conclusion aligns with a previous suggestion that thimerosal stabilizes an interaction between the IBC and SD of IP~3~R1 \[[@B29]\].

We do not know which specific cysteine residues are modified by thimerosal. Despite its subtype-selective actions ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}) and evidence that sensitization by thimerosal is mediated by cysteine residues within the NT, we have been unable to identify candidate cysteine residues from sequence data alone (see legend to Supplementary Figure S2 at <http://www.biochemj.org/bj/451/bj4510177add.htm>). Preliminary MALDI-TOF (matrix-assisted laser desorption ionization--time-of-flight) analyses were uninstructive, and it is impracticable to assay NT in which every pair of cysteine residues are mutated. It is perhaps surprising that cysteine residues in both the SD and IBC are required for thimerosal to sensitize IP~3~R1. This requirement is unlikely to result from cross-linking of a pair of cysteine residues by thimerosal because available evidence suggests that thimerosal forms a mercuryethyl adduct with a single cysteine \[[@B24]\]. An alternative possibility is that thimerosal disrupts a disulfide bridge between cysteine residues in the SD and IBC that constrains IP~3~R activation. This too seems unlikely. There is no evidence from the high-resolution structure of the NT for such a disulfide bridge \[[@B6]\]. Furthermore, IP~3~R with cysteine-less NT are not constitutively active and respond normally to IP~3~ \[[@B6]\]. We also used algorithms that predict the accessibility \[[@B51]\] and reactivity \[[@B52]\] of cysteine residues together with modelled structures of NT2--NT3 \[[@B53]\] to identify cysteine residues that might account for the differential sensitivities of IP~3~R1--IP~3~R3 to thimerosal. The results suggest that within the SD, there are two accessible cysteine residues (Cys^206^ and Cys^214^ in IP~3~R1) and they are predicted to be equally accessible in all three subtypes, but the residue equivalent to Cys^214^ in IP~3~R1 is less reactive in IP~3~R3 (Supplementary Figure S2). Within the IBC, Cys^556^ is predicted to be accessible in IP~3~R1 and IP~3~R2, but it is buried in IP~3~R3. Cys^214^ in the SD and Cys^556^ in the IBC of IP~3~R1 therefore have the properties expected to explain the sensitization of IP~3~R1 and IP~3~R2, but not IP~3~R3, by thimerosal. Further experimental work would be needed to assess this directly. We have provided the first systematic analysis of the effects of thiol reagents on each IP~3~R subtype. We conclude that thimerosal sensitizes IP~3~R1 and IP~3~R2, but not IP~3~R3, to IP~3~. It does so by modifying cysteine residues within both the SD and IBC and thereby stabilizing an active conformation of the IP~3~R.

Online data
===========
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